The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
KEYNOTE B68: Open-label phase 2 study of the efficacy and safety of pembrolizumab administered every six weeks in patients with relapsed or refractory classical Hodgkin lymphoma or primary mediastinal B-cell lymphoma.
 
Philippe Armand
Honoraria - Merck
Consulting or Advisory Role - ADC Therapeutics; AstraZeneca; Bristol-Myers Squibb; C4 Therapeutics; Celgene; Enterome; Epizyme; Genentech/Roche; GenMab; Merck Sharp & Dohme; Regeneron; Tessa Therapeutics
Research Funding - Adaptive Biotechnologies (Inst); Affimed Therapeutics (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); igm (Inst); Kite, a Gilead company (Inst); Merck Sharp & Dohme (Inst); Roche (Inst)
 
Kumudu Pathiraja
Employment - Merck Sharp & Dohme
 
Samhita Chakraborty
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Patricia Marinello
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme